When to Treat First in Metastatic NSCLC?

• by Jo Cavallo

• January 13, 2026

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

• June 9, 2026

• 5 min

Dynamic consent framework for low-dose CT scan lung cancer screening: autonomy, privacy, ethical data management

• by Jui-Chu Lin, Wesley Wei-Wen Hsiao, Jen-Wei Hu, Chien-Te Fan

• June 10, 2026

First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study

• by Wan Zhang, Xiaojun Yang, Hualin Chen, Xingxiang Pu, Reyihanguli Tuohetashi, Xuan Wu, Zhanhong Xie, Di Wu, Yongguang Cai, Shi Jin, Xuli Guo, Kaitao Yao, Yongfeng Chen, Guanming Jiang

• June 8, 2026